KRAKOW, Poland, April 26, 2021 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced the appointment of Vatnak Vat-Ho to the role of Chief Business Officer.
As Chief Business Officer, Mr. Vat-Ho will be responsible for a wide scope of corporate and business development activities at Ryvu including strategic positioning, partnering discussions, alliance management as well as investor interactions.
"I am truly honored to join the incredible team at Ryvu during such a high growth time — it's an exciting opportunity to propel an already productive platform to bring important therapeutics to patients," commented Vatnak Vat-Ho, Chief Business Officer at Ryvu Therapeutics.